港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破机构看好后续临床潜力

智通财经2025-12-23

智通财经APP获悉，荣昌生物(09995)涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。消息面上，华西证券研报指出，根据荣昌生物官方公众号，公司自主研发PD-1/VEGF双特异性抗体RC148单药一线及联合方案二线治疗非小细胞肺癌Ⅰ/Ⅱ期临床研究数据公布。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。该行表示，基于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593457234?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593457234","market":"us","top_or_hot":-1,"title":"港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荣昌生物(09995)涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。消息面上，华西证券研报指出，根据荣昌生物官方公众号，公司自主研发PD-1/VEGF双特异性抗体RC148单药一线及联合方案二线治疗非小细胞肺癌Ⅰ/Ⅱ期临床研究数据公布。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。该行表示，基于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384748.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 10:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1384748.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荣昌生物(09995)涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。消息面上，华西证券研报指出，根据荣昌生物官方公众号，公司自主研发PD-1/VEGF双特异性抗体RC148单药一线及联合方案二线治疗非小细胞肺癌Ⅰ/Ⅱ期临床研究数据公布。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。该行表示，基于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1384748.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1384748.html","article_id":"2593457234","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593457234","pubTimestamp":1766455373,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荣昌生物涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。目前公司正在积极推进相关临床：根据公司投资者调研纪要，RC148联合治疗一线非小细胞肺癌的II期临床试验已完成患者入组并计划启动联合治疗非小细胞肺癌的Ⅲ期临床研究，看好后续临床潜力。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","BK1574":"生物医药B类股","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","09995":"荣昌生物","BK1583":"高瓴概念"},"translate_title":"Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 3%, self-developed RC148 achieved a dual-path breakthrough, institutions are optimistic about follow-up clinical potential","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1.5,"09995":1.5},"content_text":"智通财经APP获悉，荣昌生物(09995)涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。消息面上，华西证券研报指出，根据荣昌生物官方公众号，公司自主研发PD-1/VEGF双特异性抗体RC148单药一线及联合方案二线治疗非小细胞肺癌Ⅰ/Ⅱ期临床研究数据公布。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。该行表示，基于RC148-C001研究的早期数据，2025年8月，RC148联合多西他赛治疗经PD-1/PD-L1 抑制剂和含铂化疗(联合或序贯)治疗失败的驱动基因阴性局部晚期或转移性非小细胞肺癌适应症已获得中国突破性治疗药物资格认定(BTD)。目前公司正在积极推进相关临床：根据公司投资者调研纪要，RC148联合治疗一线非小细胞肺癌的II期临床试验已完成患者入组并计划启动联合治疗非小细胞肺癌的Ⅲ期临床研究，看好后续临床潜力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593457234","isCrawlerRequest":true}

港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力

精彩评论

港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破机构看好后续临床潜力